Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Sarkis Clinical Trials

Neither a doctor nor a teaching hospital

Research payments

$385,408

359 payments

Through program year 2025, Sarkis Clinical Trials is reported as receiving $385,408 in research payments, across 359 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $39,671 19
2024 Research $18,722 7
2023 Research $109,538 73
2022 Research $22,108 29
2021 Research $26,206 37
2020 Research $23,010 123
2019 Research $146,153 71

Breakdown

Who paid Research payments · program years 2019–2025
  1. Supernus Pharmaceuticals, Inc. $142,489 34 payments
  2. Indivior Inc. $78,925 26 payments
  3. Teva Pharmaceuticals USA, Inc. $40,845 124 payments
  4. AbbVie, Inc. $38,361 17 payments
  5. ITI, Inc. $17,192 3 payments
  6. Boehringer Ingelheim Pharma GmbH & Co.KG $13,561 33 payments
  7. Otsuka Pharmaceutical Development & Commercialization, Inc. $11,300 2 payments
  8. ACADIA Pharmaceuticals Inc $10,500 1 payment
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $7,043 4 payments
  10. Boehringer Ingelheim International GmbH $4,763 16 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (Rbp-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-Risk Opioid Use $78,925 26 payments
  2. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Molindone Hydrochloride Extended-Release Tablets for the Treatment of Impulsive Aggression in Pediatric Patients With Attention Deficithyperactivity Disorder Adhd in Conjunction With Standard Adhd Treatment $67,631 11 payments
  3. An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia $40,845 124 payments
  4. Open-Label Extension Study to Evaluate the Safety of Molindone Hydrochloride Extended-Release Tablets for the Treatment of Impulsive Aggression in Pediatric Subjects With Attention Deficithyperactivity Disorder $29,698 10 payments
  5. Open-Label Extension Study to Evaluate the Safety of Molindone Hydrochloride Extended-Release Tablets for the Treatment of Impulsive Aggression in Pediatric Subjects With Attention Deficit/Hyperactivity Disorder $24,007 5 payments
  6. A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease $17,658 6 payments
  7. A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inadequate Response to Generalized Anxiety Disorder Treatment $17,192 3 payments
  8. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Molindone Hydrochloride Extended-Release Tablets for the Treatment of Impulsive Aggression in Pediatric Patients With Attention Deficit/Hyperactivity Disorder (Adhd) in Conjunction With Standard Adhd Treatment $15,168 2 payments
  9. Proof of concept and DRF in MDD $13,336 33 payments
  10. Acp-103-069 $10,500 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record